Background Cytomegalovirus (CMV) infection is a serious complication following heart
transplantation. This study (June 2003–January 2010) retrospectively assessed the effects …

Valganciclovir (VGCV) is considered the agent of choice after organ transplant for
cytomegalovirus (CMV) prophylaxis. The purpose of this retrospective study was to …

Despite current approaches to prophylaxis, cytomegalovirus (CMV) continues to be a
common cause of infection and disease in solid-organ-transplant patients. Thus, we …

As cytomegalovirus (CMV) disease was a leading cause of death following liver
transplantation in earlier reports, general CMV prophylaxis is widely used. We re‐evaluated …

Ganciclovir and its prodrug, valganciclovir, are more effective than acyclovir in preventing
cytomegalovirus (CMV) infection and disease in solid-organ transplant recipients. However …

This retrospective review compared oral valganciclovir (VGCV) 450 mg daily for 6 months
versus oral ganciclovir (GCV) 1000 mg 3 times daily for 3 months in preventing …

Prolonging cytomegalovirus (CMV) prophylaxis in CMV seronegative recipients of a kidney
from CMV seropositive donor (D+/R–) may reduce the incidence of late infections. We …

Purpose. The advantages and disadvantages of universal prophylaxis and preemptive
therapy and current evidence-based recommendations for preventing cytomegalovirus …

Background The frequency and significance of cytomegalovirus (CMV) infection in
seropositive (R+) heart transplant recipients (HTR) is unclear, with preventative …

Despite increasing evidence in favor of prophylactic valganciclovir treatment in kidney
transplant recipients for the prevention of cytomegalovirus (CMV) infection, the impact of …